Pass on the Deal, Put on the Watchlist
This Insight finalizes our view of the listing of Samsung BioLogics (SB) using information presented at the company’s roadshow meeting and included...
408 Views
3 Main Debatable Points to Be Discussed in Samsung BioLogics NDR This Week
Samsung BioLogics is quite busy with NDR this week. BioLogics executives are doing their best to justify the proposed valuation for BioLogics IPO....
393 Views
The Chickens Are Ready to Roost
Several recent developments confirm our thesis that Inflectra's US sales in 2017 will fall far short of management's 2017 forecast. First, Pfizer's...
337 Views
Teva May Buy Celltrion - Implications for Celltrion & Celltrion Healthcare
How should we interpret Teva's potential acquisition of Celltrion? Is this for real? Well, Teva may still be very interested in acquiring Celltrion...
377 Views
Samsung BioLogics IPO Part 3 - Valuation
Samsung BioLogics has just filed an IPO report. I will summarize Samsung BioLogics IPO report in the following three parts:Part 1 - IPO...
515 Views